Johan Van Hoof
Leiden, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.
Journal: The Lancet. Infectious diseases
Published: March 07, 2024
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: The Lancet. Infectious diseases
Published: April 13, 2022
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
Journal: The New England journal of medicine
Published: February 09, 2022
Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
Journal: Vaccine
Published: February 01, 2022
Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19.
Journal: medRxiv : the preprint server for health sciences
Published: July 16, 2021
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.
Journal: The New England journal of medicine
Published: July 14, 2021
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
Journal: The New England journal of medicine
Published: April 21, 2021
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
Journal: Nature
Published: April 15, 2021
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine.
Journal: Annals of internal medicine
Published: February 15, 2021
Last Updated: 09/26/2026